Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PB-RUTI-01
- Development stage
- Preclinical
- Lead developer
- Proxi Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
PB-RUTI-01 is a toxoid-based active immunotherapy (vaccine) candidate being developed by Proxi Biotech for the prevention and treatment of recurrent urinary tract infections (rUTI). The vaccine utilizes a toxoid-based platform designed to elicit protective immunity against pathogens that cause UTIs, particularly those associated with antimicrobial resistance (AMR). By targeting bacterial toxins or virulence factors, the immunotherapy aims to trigger a robust immune response to prevent infection recurrence. As of early 2024, the program is in the discovery and preclinical stages of development, with Croda Pharma serving as a strategic partner for the project.
Beyond the preview
Go deeper on PB-RUTI-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PB-RUTI-01.